StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3010% above fair value
$923.34−22.19 (-2.35%)

Close on Nov 19, 2026Market cap $95.52BP/E 20.4Yield –

Regeneron Pharmaceuticals EYLEA (2 mg) — U.S. Net Product Sales by Quarter

EYLEA (2 mg) — U.S. Net Product Sales ($M) ($M)

Regeneron Pharmaceuticals EYLEA (2 mg) — U.S. Net Product Sales: $400M in Q3 2026, down 41.3% from a year earlier.

Latest, Q3 2026
400
Period ended Sep 30, 2026
Change on a year earlier
-41.3%
681 in Q3 2025
History
59 quarters
Since Q1 2012
Sources
51
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-10-30) ↗

Reported in Form 10-Q / 10-K Note — Net Product Sales (XBRL) & Table 5.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEYLEA (2 mg) — U.S. Net Product Sales ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026400-41.3%Form 10-Q (filed 2026-10-30) ↗
Q2 2026Jun 30, 2026412-45.4%Form 10-Q (filed 2026-07-30) ↗
Q1 2026Mar 31, 2026473-35.7%Form 10-Q (filed 2026-04-29) ↗
Q4 2025Dec 31, 2025577-51.5%Form 10-K (filed 2026-02-04) ↗
Q3 2025Sep 30, 2025681-40.5%Form 10-Q (filed 2026-10-30) ↗
Q2 2025Jun 30, 2025754-38.7%Form 10-Q (filed 2026-07-30) ↗
Q1 2025Mar 31, 2025736-38.7%Form 10-Q (filed 2026-04-29) ↗
Q4 2024Dec 31, 20241,190-11.0%Form 10-K (filed 2026-02-04) ↗
Q3 2024Sep 30, 20241,145-21.0%Form 10-Q (filed 2025-10-28) ↗
Q2 2024Jun 30, 20241,231-18.0%Form 10-Q (filed 2025-08-01) ↗
Q1 2024Mar 31, 20241,202-16.2%Form 10-Q (filed 2025-04-29) ↗
Q4 2023Dec 31, 20231,338-10.6%Form 10-K (filed 2026-02-04) ↗
Q3 2023Sep 30, 20231,448-11.1%Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 20231,500-7.5%Form 10-Q (filed 2024-08-01) ↗
Q1 2023Mar 31, 20231,434-5.5%Form 10-Q (filed 2024-05-02) ↗
Q4 2022Dec 31, 20221,496-3.3%Form 10-K (filed 2025-02-05) ↗

Breakdown

What makes up EYLEA (2 mg) — U.S. Net Product Sales

Cite this data

StockData. (2026). Regeneron Pharmaceuticals EYLEA (2 mg) — U.S. Net Product Sales ($M), quarterly Q1 2012–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rev-eylea-2mg-us

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?